Cleveland Clinic and Ascension Ventures contributed to a $15.8m round for Cardionomic, which is developing a neuromodulation system to treat heart failure.
US-based cardiac treatment device developer Cardionomic has received $15.8m from investors including healthcare provider Cleveland Clinic and corporate-backed fund Ascension Ventures, Twin Cities Business, has reported, citing a regulatory filing.
Venture capital firm New Enterprise Associates (NEA) also took part in the round, which has a $16.9m target for its close. Ascension Ventures represents 13 healthcare providers including Ascension Health.
Cardionomic is working on a neuromodulation-based treatment for acute decompensated heart failure, where poor blood circulation pushes excess fluids into…
